Dasatinib induces lymphocytosis without altering homing to SLOs. (A) Lymphocytosis assay in C57BL/6J mice. (B) Blood obtained 2 hours after the administration of DMSO (vehicle) or 50 mg/kg dasatinib (Dasa) was immunophenotyped to quantify leukocyte subpopulations by flow cytometry; n = 5 mice per group from 2 independent experiments. Boxplots depict 25th and 75th percentiles and the median, and the whiskers show fifth and 95th percentiles. Analyzed by Kruskal-Wallis test and Dunn multiple comparisons test. (C) Effect of dasatinib on adhesion and crawling of murine lymphocytes under shear flow. Detachment rate (percentage of detached cells after 5 minutes of high shear; mean ± standard deviation) (left). Proportion of crawling and stationary cells (middle). Speed of crawling cells (right). n = 3; analyzed by Mann-Whitney U test. (D) Experimental layout for in vivo homing assay. (E) Ratio of dasatinib-treated and control (DMSO-treated) lymphocytes recovered for each organ. Red lines indicate the mean. A ratio of 1 indicates equal recovery. n = 3 independent experiments; analyzed by 1-sample t test. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001. CFSE, carboxyfluorescein diacetate succinimidyl ester; mLN, mesenteric LN; pLN, peripheral LN.